title: [Effect of an oral anti-estrogen agent (mepitiostane) on the regression of intracranial meningiomas in the elderly].
abstract: We report here the regression of meningioma following treatment with the anti-estrogen agent mepitiostane in a series of cases. The first case was that of a 72-year-old woman who presented with coma status due to non-communicating hydrocephalus. A large presumed meningioma within the cerebello-pontine angle was detected on gadolinium-enhanced magnetic resonance imaging (MRI). The patient recovered from the neurological deficit following endoscopic third ventriculostomy treatment, and was administered mepitiostane (10mg/day) orally. Gadolinium-enhanced MRI showed a marked regression (85%) of the meningioma following 60 months of oral medication. The second case was that of a 79-year-old woman with no neurological deficit; however, a presumed meningioma located in the frontal skull base was detected on gadolinium-enhanced MRI. Mepitiostane (10mg/day) was administered orally. Again, a marked regression (88%) of the meningioma was demonstrated after 115 months of oral medication. The third case was that of a 71-year-old woman who presented with right visual disturbance and a visual field defect. Gadolinium-enhanced MRI demonstrated a presumed meningioma located in the left sphenoidal bone. Mepitiostane (20mg/day) was administered orally. An 79% regression of the meningioma was observed after 21 months of oral medication. In these three cases, the marked reduction in meningioma following anti-estrogen agent (mepitiostane) administration suggested that this oral medication could be an effective therapeutic option in elderly patients.
authors.affiliation: Department of Neurosurgery, Japanese Red Cross Takayama Hospital.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Miyai
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Takenaka
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Hayashi
authors.forename: Masayasu
authors.initials: M
authors.lastname: Kato
authors.forename: Kodai
authors.initials: K
authors.lastname: Uematsu
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Murai
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000732:Androstanols / Q000008:administration & dosage / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008577:Meningeal Neoplasms / Q000188:drug therapy*; D008579:Meningioma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000732:Androstanols; D004965:Estrogen Antagonists; C006242:mepitiostane